Menu
Home / Guides / Tirzepatide microdosing
Thinking about a lower dose? Read this first.
Microdosing Tirzepatide (2026): What a Low Dose Can and Can’t Do
By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD (NPI 1144260043) · Updated
Tirzepatide microdosing means taking less than Zepbound’s labeled doses, usually under its 2.5 mg starting dose. No trial has tested it as a way to manage weight, and the label has no microdose (read November 1, 2026); your provider decides your dose. At NexLife, compounded tirzepatide is $115 a month on the 12-month plan, or $129 month to month, at every dose, microdose included.
$115/mo on 12 months, every dosePrice Match Guarantee†
- No microdose on Zepbound’s label: 2.5 mg is its lowest dose, for starting only
- Below 2.5 mg: one small trial group, where weight barely changed
- Your provider decides your dose, and your price stays the same

$115/mo on a 12-month plan, all-inclusive, same price at every dose
Or $129/mo month to month
Microdose or full dose: your price stays the same at every dose
About 3 minutes of health questions · No insurance needed · Not prescribed? No charge for medication
See all 4 plans and what a year costs
| Plan | Per month | 12 months at this rate |
|---|---|---|
| 12-month Most savings | $115 | $1,380 |
| 6-month | $119 | $1,428 |
| 3-month | $125 | $1,500 |
| Month to month | $129 | $1,548 |
Month to month costs $168 more over 12 months than the 12-month plan. Month to month is billed monthly; the 3-, 6- and 12-month plans are paid upfront at checkout ($375, $714 or $1,380). Plans renew until you cancel.
Price Match Guarantee†. Paying less elsewhere? We match your regular monthly price. How it works
4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026)LegitScript-certified
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. The vial shown is an illustration. Always use the strength on your pharmacy’s label.
- Licensed U.S. providers
- LegitScript certified
- Free expedited shipping
- HSA, FSA, Affirm, Klarna, Afterpay
- 24/7 support, real people
- Filled by Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA)
At a glance
What should you know about tirzepatide microdosing?
The short answers, from Zepbound’s label and the trials. Each one is explained below.
| Question | Answer |
|---|---|
| What is microdosing? | Taking less than the label’s doses, usually below the 2.5 mg starting dose, or splitting a weekly dose in two. There’s no official definition. |
| Is it FDA-approved? | No. Zepbound’s label has no microdose, and its lowest dose, 2.5 mg, is only for starting treatment. |
| Has it been tested? | Not as a way to manage weight. Below 2.5 mg, the only randomized data we found is a 1 mg group in a 26-week diabetes trial: weight changed −0.9 kg, against −0.4 kg on placebo. |
| Fewer side effects? | Possibly fewer stomach side effects, which rose with dose in trials, but no trial measured them on a microdose. The label’s warnings apply at every dose. |
| A gentler start instead? | That’s on the label: each step up comes after at least 4 weeks on the current dose, so your provider can hold a dose longer. |
| What does NexLife charge? | $115 a month on the 12-month plan, or $129 month to month, at every dose, microdose included. |
The trials studied FDA-approved Zepbound or tirzepatide made by Lilly; compounded tirzepatide wasn’t studied, and it isn’t FDA-approved. NexLife’s prices as of November 5, 2026.
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- No microdose is on Zepbound’s label. Its lowest dose, 2.5 mg, is for the first 4 weeks only.
- The evidence below 2.5 mg is thin. In a 2018 trial, 1 mg a week lowered blood sugar in type 2 diabetes but barely changed weight over 26 weeks.
- Weight loss grew with dose in SURMOUNT-1: 15.0% on average at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg over 72 weeks, against 3.1% on placebo.
- Wellness and longevity claims aren’t backed by trials. Lilly says it has no data on the benefits or risks of microdosing.
- Small doses mean small volumes. At an example strength of 10 mg per mL, 1 mg is 10 units, and each unit is 0.1 mg.
- At NexLife, every dose costs the same: $115 a month on the 12-month plan, or $129 month to month.
The basics
What is tirzepatide microdosing?
Taking less than Zepbound’s labeled doses, usually under its 2.5 mg starting dose, but there’s no official definition. People use the word for three different plans, and none of them is on Zepbound’s label (revised August 2026). A fourth option, a slower climb, is on the label.
| What people mean | What it looks like | On Zepbound’s label? |
|---|---|---|
| A dose below 2.5 mgthe usual meaning | A weekly dose under the starting dose. Noom’s microdose plan, for example, lists 1 to 3 mg a week. | No: 2.5 mg is the lowest dose |
| Staying at a starting dose | Holding 2.5 mg for months instead of stepping up. | No: 2.5 mg is for starting only |
| Splitting the weekly dose | Half the dose, twice a week, as Remedy Meds offers. | No: every dose is once a week |
| Climbing more slowlynot microdosing | Holding each step longer before the next one. | Yes: each step comes after at least 4 weeks |
Swipe the table sideways to see every column.
Four ways people lower their tirzepatide dose, against the Zepbound prescribing information (revised August 2026), read November 15, 2026. Example plans are from programs’ own pages, checked November 1, 2026.
“The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.”
Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised August 2026
Why a microdose means compounded tirzepatide. Zepbound’s pens and vials come only in set doses, from 2.5 mg to 15 mg. A dose below 2.5 mg has to be measured with a syringe from a compounded vial, and compounded tirzepatide isn’t FDA-approved.
A slower climb is the labeled option. The label raises the dose in 2.5 mg steps, each “after at least 4 weeks on the current dose,” so your provider can keep you on a step longer if side effects are the problem.
Why people ask
Why do people consider microdosing tirzepatide?
Five reasons come up most. For each one, there’s a better-studied option to ask your provider about first.
| Why people ask | What the evidence says | Ask your provider about |
|---|---|---|
| Side effects on the way up | Stomach side effects were most common while the dose was going up. In SURMOUNT-MAINTAIN, they affected 14% of people on 10 or 15 mg, 7% on 5 mg and 3% on placebo. | Holding a step longer, or a lower maintenance dose |
| Keeping weight off after a goal | No trial tested a microdose for this. Stepping down to 5 mg held most of the loss, on average, in SURMOUNT-MAINTAIN. | Whether 5 mg, the label’s lowest maintenance dose, fits you |
| Cost | A smaller dose uses less medicine, but many programs charge one price at every dose, and the microdose plans we track cost $149 to $199 a month after any first-month offer. | The price at your dose, in writing |
| A lower BMI | Zepbound’s FDA line is a BMI of 30 or more, or 27 or more with a weight-related condition. Below that line, any dose is off-label. | Whether the benefits outweigh the risks for you |
| Wellness, longevity or inflammation | Not shown in trials. A 2026 review found the direct evidence for GLP-1 microdosing “extremely limited,” News-Medical reports, and Lilly says it has no microdosing data. | What you hope to gain, and how you’d measure it |
Swipe the table sideways to see every column.
Why people consider a tirzepatide microdose, what the evidence on this page says, and what to ask instead. From the Zepbound prescribing information (revised August 2026), SURMOUNT-MAINTAIN (The Lancet, 2026) and programs’ own pages, checked November 15, 2026.
The evidence
What do trials show about low doses of tirzepatide?
The dose matters. In a 2018 trial, 1 mg a week barely moved weight over 26 weeks; in SURMOUNT-1, weight loss grew with each labeled dose: on average, 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg. No trial has tested microdosing as a plan.
| Trial | Who and how long | Lowest dose tested | Highest dose tested | Placebo |
|---|---|---|---|---|
| 2018 dose-finding trialFrias et al., The Lancet | 318 adults with type 2 diabetes, 26 weeks | 1 mg: −0.9 kg | 15 mg: −11.3 kg | −0.4 kg |
| SURMOUNT-1Jastreboff et al., NEJM, 2022 | 2,539 adults with obesity or overweight, without diabetes, 72 weeks | 5 mg: −15.0% | 15 mg: −20.9% | −3.1% |
| SURMOUNT-MAINTAINHorn et al., The Lancet, 2026 | 378 adults who had lost weight on 10 or 15 mg, then a year on that dose, 5 mg or placebo | 5 mg: +7.0% in the year | 10 or 15 mg: −0.2% in the year | +15.2% in the year |
Swipe the table sideways to see every column.
Three randomized trials of tirzepatide, from the lowest dose each tested to the highest: a 26-week dose-finding trial in 318 adults with type 2 diabetes (Frias et al., The Lancet, 2018), SURMOUNT-1 in 2,539 adults with obesity or overweight and without diabetes (Jastreboff et al., NEJM, 2022) and SURMOUNT-MAINTAIN (Horn et al., The Lancet, 2026). Different trials and people: kilograms in the first, percent of body weight in the others. They studied tirzepatide made by Lilly; compounded tirzepatide wasn’t studied.
Counting everyone randomized: 2,539 adults with obesity or overweight and without diabetes (Jastreboff et al., NEJM, 2022). Averages, not a prediction for you. The trial studied tirzepatide made by Lilly; compounded tirzepatide wasn’t studied.
1 mg wasn’t inactive. In the 2018 trial, HbA1c fell 1.06 points on 1 mg, against 0.06 on placebo, in people with type 2 diabetes. Its effect on weight was small: −0.9 kg (about 2 lb), against −0.4 kg on placebo.
Fewer side effects, and less effect. In the same trial, 50% of people on 1 mg reported a side effect of any kind, close to the 52.9% on placebo, against 72.7% to 84.9% on 5 to 15 mg.
No microdosing trial. We found no randomized trial of tirzepatide microdosing for weight, maintenance or wellness, as of November 5, 2026. Lilly says it has no data on the benefits or risks of microdosing.
“Lilly does not have any data on the benefits or risks of microdosing of Zepbound or Mounjaro.”
Eli Lilly and Company, quoted by ConsumerAffairs, GLP-1 microdoses not a good idea, doctors warn, January 16, 2026
What a 2026 review found. A narrative review in Cureus (2026) gathered indirect evidence, such as an observational study of low-dose tirzepatide and a single case report, and said prospective studies are needed. Its authors say the benefits of standard doses can’t be assumed to persist at fractional doses, News-Medical reports.
Side effects
Does microdosing tirzepatide cause fewer side effects?
Possibly fewer stomach side effects, since they rose with dose in trials. But no trial has measured side effects on a microdose, Lilly says it has no data on the benefits or risks of microdosing, and the label’s warnings apply at every dose.
| Side effect or risk | What the trials and label show | At a lower dose |
|---|---|---|
| Nausea, vomiting, diarrhea | Nausea affected 25% to 29% of people in Zepbound’s trials, versus 8% on placebo, mostly while the dose was going up. | Likely less common: 7% on 5 mg against 14% on 10 or 15 mg, in SURMOUNT-MAINTAIN |
| Thyroid C-cell tumorsboxed warning | Caused tumors in rodents; it isn’t known whether it does in people. Don’t use it with a personal or family history of MTC, or with MEN 2. | The warning isn’t tied to dose |
| Pancreatitis, gallbladder problems | Serious side effects listed on the label. | Still possible: the warnings apply at every dose |
| Low blood sugar | Likelier with insulin or a sulfonylurea, the label says. | Still possible with those medicines |
| Birth control pills | Tirzepatide can make them less effective for 4 weeks after you start and for 4 weeks after each dose increase. | Applies when you start and at each increase |
| Dosing errors | The FDA has reported dosing errors with compounded GLP-1 medicines, often from mix-ups between units, mL and mg. | Higher risk: small volumes leave less room for error |
Swipe the table sideways to see every column.
From the Zepbound prescribing information (revised August 2026), SURMOUNT-MAINTAIN (The Lancet, 2026) and the FDA. No trial measured side effects on a microdose. The trials studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
Get help fast. Severe stomach pain that won’t go away: call your provider right away. Swelling of your face or throat, or trouble breathing: get emergency care.
More detail. What’s common, what’s serious and what helps: tirzepatide side effects.
Off-label chart
Tirzepatide microdosing chart: how many units is each dose?
On a U-100 insulin syringe, units = dose in mg ÷ vial strength in mg/mL × 100, so the same microdose is a different number of units in every vial. At 10 mg/mL, 2.5 mg is 0.25 mL, or 25 units, and 1 mg is 10 units.
Read this first: this is off-label math, not a dosing plan. Microdosing isn’t FDA-approved, and no trial has tested it as a way to manage weight; Zepbound’s lowest labeled dose is 2.5 mg a week. Use the chart only to check a dose your prescriber wrote, against the strength in mg/mL on your pharmacy label. Never convert a dose without that number.
| Weekly dose | 5 mg/mL | 10 mg/mL | 15 mg/mL | 20 mg/mL | 25 mg/mL | 30 mg/mL |
|---|---|---|---|---|---|---|
| 0.5 mg | 10 units | 5 units | 3.3 units | 2.5 units | 2 units | 1.7 units |
| 1 mg | 20 units | 10 units | 6.7 units | 5 units | 4 units | 3.3 units |
| 1.5 mg | 30 units | 15 units | 10 units | 7.5 units | 6 units | 5 units |
| 2 mg | 40 units | 20 units | 13.3 units | 10 units | 8 units | 6.7 units |
| 2.5 mgZepbound’s starting dose | 50 units | 25 units | 16.7 units | 12.5 units | 10 units | 8.3 units |
Swipe the table sideways to see every column.
The math: units = dose in mg ÷ strength in mg/mL × 100, and mL = units ÷ 100. At 10 mg/mL, each unit holds 0.1 mg, so 1 unit off on a 1 mg dose is a 10% error. At 30 mg/mL, 0.5 mg is just 1.7 units, hard to measure on a syringe marked in 1- or 2-unit lines. Syringes can’t measure tenths of a unit: ask your pharmacist how to measure any dose that isn’t a whole number of units.
These strengths are examples only. They match the columns of our tirzepatide dosage chart, and compounded strengths vary by pharmacy. 25 mg/mL is also the strength of Zepbound’s 15 mg multi-dose vial on its FDA label (60 mg in 2.4 mL). Your vial’s label decides the strength, and your prescription sets your dose.
Check before you draw. The FDA has reported dosing errors with compounded semaglutide, and says mix-ups between milliliters, milligrams and units may have contributed. If a number doesn’t match your prescription, ask your provider before you inject; at NexLife, call or text
A small dose can outlast its vial. USP Chapter 797, the sterile-compounding standard, calls for throwing out a multiple-dose vial 28 days after its first use, even if medicine is left, or by its beyond-use date if that comes first. On a microdose, there may be medicine left on day 28: throw it out anyway. More: compounded tirzepatide storage.
After your goal
Can microdosing tirzepatide keep weight off?
Microdosing tirzepatide to keep weight off hasn’t been tested. The label’s lowest maintenance dose is 5 mg, and it’s the only lower dose a maintenance trial has tested: on average, it held most of the loss. Your provider decides your dose.
| After 60 weeks at 10 or 15 mg | Weight change in the maintenance year | Kept 80% or more of their loss* |
|---|---|---|
| Stayed on their dose140 people | −0.2% (held steady) | 77.5%, about 3 in 4 |
| Stepped down to 5 mg144 people | +7.0% | 42.4%, about 2 in 5 |
| Switched to placebo94 people | +15.2% | 10.4%, about 1 in 10 |
| Below 5 mg, or a microdosenot in the trial | Not tested | Not tested |
Swipe the table sideways to see every column.
SURMOUNT-MAINTAIN (Horn et al., The Lancet, 2026), counting everyone randomized. *Among people whose weight had leveled off by week 60. This trial studied FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
Fewer stomach side effects on 5 mg. In the maintenance year, nausea, vomiting or diarrhea affected 14% of people on the full dose, 7% on 5 mg and 3% on placebo.
Thinking of going below 5 mg? Agree with your provider how you’ll track your weight, and when you’ll check back in. The whole picture: tirzepatide maintenance dose.
Claims vs. evidence
Tirzepatide microdosing claims: what does the evidence support?
Microdosing is often marketed for more than weight. Here’s what the trials, reviews and statements on this page support, and what they don’t.
| The claim | What we found |
|---|---|
| It causes fewer side effects | Plausible: side effects rose with dose in trials. But no trial measured them on a microdose. |
| It works like a full dose | Not for weight, on the evidence we found. Weight loss grew with dose, and 1 mg a week barely changed weight in 26 weeks. |
| It keeps weight off | Not tested below 5 mg. Stepping down to 5 mg held most of the loss, on average, in SURMOUNT-MAINTAIN. |
| It lowers inflammation or slows aging | Not shown in trials. Researchers quoted by STAT say there’s no robust clinical evidence that very small doses work, and Lilly says it has no microdosing data. |
| It’s FDA-approved | No. No FDA label includes a microdose, and compounded tirzepatide isn’t FDA-approved. |
| It costs less | Not always. The microdose plans we track cost $149 to $199 a month after any first-month offer (checked November 15, 2026). At NexLife, it’s $115 a month on the 12-month plan, or $129 month to month, at every dose. |
Swipe the table sideways to see every column.
From the trials, the 2026 review, Lilly’s statement and programs’ pages cited on this page, read November 1 to 5, 2026.
Brand-name options
Can you microdose Zepbound or Mounjaro?
Not as labeled. Every Zepbound pen and vial gives a set dose, from 2.5 mg to 15 mg, and no form gives less than 2.5 mg.
| Zepbound form | How the dose works | Self-pay at LillyDirect |
|---|---|---|
| Single-dose vial | One set dose per vial, drawn with a syringe | $299 at 2.5 mg, $399 at 5 mg, and $449 from 7.5 mg, with a refill within 45 days |
| KwikPen | Four weekly doses in one pen; the dose is set for you | From $299 a month |
| Single-dose pen | One set dose per pen | See Zepbound cost without insurance |
Swipe the table sideways to see every column.
From the Zepbound prescribing information (revised August 2026) and LillyDirect, checked November 15, 2026. $449 from 7.5 mg needs a refill within 45 days; otherwise it’s $499 to $699. Prices are for the medication alone.
Pens and vials are made for set doses. The label has no partial doses, so splitting a pen or a single-dose vial isn’t a labeled use. Mounjaro, tirzepatide for type 2 diabetes, also starts at 2.5 mg.
On Medicare? Since July 1, 2026, Medicare’s GLP-1 Bridge lets eligible Part D enrollees get the Zepbound KwikPen for weight loss at a $50 monthly copay, with prior authorization (approval before it’s covered), through December 31, 2027.
Compare them. Tirzepatide pen vs. vial, and brand-name prices: Zepbound cost without insurance.
The rules
Is compounded tirzepatide microdosing legal?
Compounded tirzepatide microdosing can be legal: a licensed provider prescribes it for you, a state-licensed 503A pharmacy (one that compounds for individual patients’ prescriptions) prepares it, and your prescriber documents a significant difference for you. It isn’t FDA-approved, and no microdose regimen is.
“…unless a prescriber determines and documents the compounded drug product contains a change that produces a significant difference from the commercially available drug product for an identified individual patient.”
U.S. Food and Drug Administration, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (April 1, 2026)
A dose strength you can’t buy. Pharmacy Times lists the need for a dose strength that isn’t commercially available among the narrow exceptions for 503A pharmacies (May 1, 2026). Whether it applies to you is your prescriber’s call, and it has to be documented.
503B facilities can’t make it from bulk tirzepatide. The FDA proposed on April 30, 2026 to exclude tirzepatide from the 503B bulks list; when we checked on November 5, 2026, we found no final decision.
Every rule, in the FDA’s words. See is compounded tirzepatide legal?
Cost
What does tirzepatide microdosing cost?
The microdose plans we track cost $149 to $199 a month after any first-month offer (checked November 15, 2026). At NexLife, a microdose costs what every dose does: $115 a month on the 12-month plan, or $129 month to month.
| Program | What it is | To start | Then, a month | First 12 months |
|---|---|---|---|---|
| NexLife, 12-month plancompounded | Any dose your provider prescribes, microdose included | $115 | $115 | $1,380 |
| NexLife, month to monthcompounded | Any dose your provider prescribes, microdose included | $129 | $129 | $1,548 |
| Raeliva microdosecompounded | A low-dose plan, offered “for metabolic support as part of a longevity plan rather than for weight loss” | $149 | $149 | $1,788 |
| Noom microdose plancompounded | Low-dose tirzepatide, 1 to 3 mg a week; billed $597 every 12 weeks | $99 the first 4 weeks | $199 | $2,288 |
| Zepbound at LillyDirect, 2.5 mgbrand-name; a starting dose, not a microdose | The medication alone | $299 per 4 weeks | $299 per 4 weeks | Not a dose to stay on |
Swipe the table sideways to see every column.
Prices as each company lists them: Noom, Raeliva and LillyDirect checked November 1, 2026; NexLife’s as of November 5, 2026. First 12 months is our math: at Noom, the first 4-week price, then 11 more 4-week supplies (48 weeks in all); at Raeliva and NexLife, 12 months at the monthly price. Noom’s prices are before tax. NexLife’s prices include the provider and shipping; LillyDirect’s is for the medication alone. Compounded medicines aren’t FDA-approved; Zepbound is.
Our math from each company’s listed prices: Noom and Raeliva checked November 1, 2026; NexLife’s as of November 5, 2026. Noom’s months are 4-week supplies. NexLife’s price is the same at every dose. The medicines are compounded, not FDA-approved.
Month one at Noom costs less. Its $99 start is $16 below NexLife’s 12-month plan. From month two, its $199 is $84 a month more than NexLife’s 12-month plan, and $70 more than NexLife month to month.
NexLife Price Match Guarantee†. Already on compounded tirzepatide with another licensed provider, and paying less? We match your regular monthly price. How it works
Ask for the price at your dose, in writing. Some programs price by dose, and some charge one price at every dose. A dose tier or a dose step can change what you pay. Our Price Match Guarantee† matches regular month-to-month prices, not first-month offers or prepaid multi-month programs.
Compare more. Every dose, priced: tirzepatide cost by dose. One price at every dose: flat-rate tirzepatide. Our reviews: Noom, Raeliva and Remedy Meds.
Is it for you?
Who shouldn’t microdose tirzepatide?
Anyone who shouldn’t take tirzepatide at any dose. A lower dose doesn’t change who the label says shouldn’t use it, or what to tell your provider first.
| If you | What the label says |
|---|---|
| Have had medullary thyroid carcinoma (MTC), or a family member has, or you have MEN 2 | Don’t use tirzepatide, at any dose. |
| Have had a serious allergic reaction to tirzepatide | Don’t use it. |
| Are pregnant, or planning to be | Tell your provider. The label says to stop Zepbound once a pregnancy is recognized. |
| Take insulin or a sulfonylurea | Low blood sugar is likelier; your provider may adjust those medicines. |
| Take birth control pills | Switch to a non-oral method, or add a barrier method, for 4 weeks after you start and for 4 weeks after each dose increase. |
| Take another GLP-1 medicine | Don’t combine them. |
| Have had pancreatitis, gallbladder or kidney problems, severe stomach problems, or eye problems from diabetes | Tell your provider before you start. |
Swipe the table sideways to see every column.
From the Zepbound prescribing information (revised August 2026). Not a complete list: your provider reviews your full health history.
With your provider
How do you talk to your provider about a lower dose?
Start with what you want the lower dose to do. Then you can weigh a microdose against the labeled options together.
Say what you want from it
Fewer side effects, a lower cost, keeping weight off or something else: each one leads to a different plan.
Ask about the labeled options first
A slower climb, with at least 4 weeks on each step, or 5 mg, the label’s lowest maintenance dose.
Agree on what you’ll watch
If you try a microdose, settle how you’ll track your weight and side effects, and when you’ll check back in.
Get the math in writing
Your dose in mg, your vial’s strength in mg per mL, the units to draw, and the date to throw the vial out.
Make every change together
Any change to your dose or your schedule goes through your provider.
At NexLife
How does tirzepatide microdosing work at NexLife?
A licensed provider makes the call: after reviewing your health history, they decide whether to prescribe and at what dose, microdose included. You pay one price at every dose, $115 a month on the 12-month plan or $129 month to month, and refills ship free. Compounded tirzepatide isn’t FDA-approved.
A licensed provider decides whether a microdose fits you, and your price doesn’t change with your dose. Here’s how it works.
A provider decides your dose
A licensed provider reviews your health history and decides whether to prescribe, and at what dose, including whether a microdose is right for you.
One price at every dose
$115 a month on the 12-month plan, or $129 month to month. A microdose costs what 15 mg does.
Clear dose instructions
Your label shows the strength in mg per mL, and your provider tells you your dose. Real people answer 24/7 at
(949) 818-8000 .Each refill ships free
Expedited shipping; most orders ship within 1 to 2 business days.
See the program. Plans and how to start: the microdose tirzepatide program. A nutrition plan and a 1:1 coaching call are included.
Paying with an HSA or FSA? NexLife takes HSA and FSA cards and provides a letter of medical necessity if your plan asks for one. Affirm, Klarna and Afterpay are offered at checkout too.
Loved by our members
Real stories from NexLife members about their care and service.
A selection of 5-star reviews from Trustpilot, quoted in full as written. Results vary from person to person, and weight loss isn’t guaranteed.
★★★★★TrustScore 4.8 out of 5 on Trustpilot407 reviews as of Nov. 15, 2026 · Read them all ↗
★★★★★Read on Trustpilot ↗
“Excellent visit. Dr. Kennah was very knowledgeable and helpful and answered all my questions.”
Ethan B.
★★★★★Read on Trustpilot ↗
“That’s a real site with good prices and plans!”
Estefany L.
★★★★★Read on Trustpilot ↗
“Affordable, quick and easy. They could not have made it a smoother less stressful experience.”
Andisheh K.
★★★★★Read on Trustpilot ↗
“Great communication. Easy to work with. They work to set you up for success.”
Anthony C.
★★★★★Read on Trustpilot ↗
“Fast delivery and easy to get a hold of when needing to talk with someone!”
Browneyes
★★★★★Read on Trustpilot ↗
“So happy with NexLife. Communication has been great, I’m recommending them to all my friends.”
April
★★★★★Read on Trustpilot ↗
“Very happy so far”
Tammy E.
★★★★★Read on Trustpilot ↗
“Fast service great communication!! Willing to work with you!”
Bon
★★★★★Read on Trustpilot ↗
“Great service and excellent communication!”
Gabrielle D.
★★★★★Read on Trustpilot ↗
“Easy and pricing not bad! Customer service was helpful in answering my questions.”
Lyndy T.
★★★★★Read on Trustpilot ↗
“Good experience, great team”
Mai S.
★★★★★Read on Trustpilot ↗
“Great communciation and was fast and reliable”
Kiki
Names are shortened for privacy. Reviews are members’ opinions, not medical advice.
What does NexLife cost?
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†
GIP + 12-month plan $115/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan, $1,380 paid upfront; $129/mo month to month, billed monthly.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication

12-month plan $95/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
TrustScore 4.8 out of 5 on Trustpilot 407 reviews as of Nov. 15, 2026 · Read them all ↗
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms
The NexLife Price Match Guarantee†
Paying less elsewhere?
Keep your price. Upgrade your care.
Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.
- 1Send a receipt from the last 60 days
- 2A NexLife provider reviews your prescription
- 3Pay your matched price, at every dose
Locked while your plan is activeSame price at every doseNo membership fee
†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.
Tirzepatide microdosing: your questions
Fair questions about NexLife
- Will a microdose cost less?
- No. You pay the same at every dose, microdose included.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
What is tirzepatide microdosing?
Taking less tirzepatide than Zepbound’s labeled doses, usually below the 2.5 mg starting dose, or splitting a weekly dose in two. There’s no official definition, and no FDA label includes a microdose. Your provider decides your dose.
What is a microdose of tirzepatide in mg?
There’s no set amount. Programs often mean a dose below 2.5 mg a week; Noom’s microdose plan, for example, lists 1 to 3 mg (checked November 1, 2026). Zepbound’s lowest dose, 2.5 mg, is only for starting treatment. Your prescription sets your dose.
Does microdosing tirzepatide work for weight loss?
It hasn’t been tested as a weight-loss plan. In a 2018 trial in type 2 diabetes, weight changed −0.9 kg over 26 weeks on 1 mg a week, against −0.4 kg on placebo. In SURMOUNT-1, weight loss grew with dose, from 15.0% at 5 mg to 20.9% at 15 mg over 72 weeks. These trials studied tirzepatide made by Lilly, not compounded tirzepatide.
Is tirzepatide microdosing FDA-approved?
No. Zepbound’s label has no microdose: its doses run from 2.5 mg, for starting only, to 15 mg. Compounded tirzepatide isn’t FDA-approved either; a provider prescribes it only when it offers a significant difference for you.
Does microdosing tirzepatide reduce side effects?
It may reduce stomach side effects, which rose with dose in trials, but no trial has measured side effects on a microdose. In SURMOUNT-MAINTAIN, nausea, vomiting or diarrhea affected 7% of people on 5 mg and 14% on 10 or 15 mg. The label’s warnings, including the boxed warning on thyroid tumors, apply at every dose.
How many units is a microdose of tirzepatide?
It depends on your vial’s strength. At an example strength of 10 mg per mL, 1 mg is 0.1 mL, or 10 units on a U-100 syringe; at 25 mg per mL, it’s 4 units. Use the strength on your own vial’s label, and ask your provider if the numbers don’t match.
Can I microdose tirzepatide to keep weight off?
It hasn’t been tested. The label’s lowest maintenance dose is 5 mg: in SURMOUNT-MAINTAIN, stepping down to 5 mg held most of the loss, on average, with weight up 7.0% in a year, against 15.2% on placebo. Your provider can help you weigh your options.
Can I split my tirzepatide dose into two shots a week?
Not by the label: Zepbound is taken once a week, and no trial on this page tested twice-weekly dosing. Some programs offer it, such as Remedy Meds’ half the dose, twice a week. If you’re on a split schedule, tell any new provider.
Can I microdose with a Zepbound pen?
No. Zepbound’s pens, KwikPen and vials each give a set dose, from 2.5 mg to 15 mg, and the label has no partial doses. A dose below 2.5 mg needs a compounded vial and a syringe.
How long does a vial last on a microdose?
No more than 28 days after its first use, or until its beyond-use date if that comes first, even if medicine is left. That’s the USP Chapter 797 standard for multiple-dose vials. On a small dose, ask how much medicine each vial holds.
Can I microdose tirzepatide with a lower BMI?
Zepbound’s FDA line is a BMI of 30 or more, or 27 or more with a weight-related condition; below it, any dose is off-label. NexLife’s microdose program pages say microdose options may be available from a BMI of 23. A licensed provider decides only after reviewing your health history.
Does microdosing tirzepatide help with inflammation or aging?
That hasn’t been shown. A 2026 review found the direct evidence for GLP-1 microdosing extremely limited, News-Medical reports, and Lilly says it has no data on the benefits or risks of microdosing Zepbound or Mounjaro.
How much does microdosing tirzepatide cost at NexLife?
$115 a month on the 12-month plan, or $129 month to month: the same price at every dose, microdose included. That’s $1,380 or $1,548 a year, with no membership fee.
Is microdosing cheaper than a full dose?
Not always. At NexLife and many other programs, every dose costs the same. The microdose plans we track cost $149 to $199 a month after any first-month offer (checked November 1, 2026). Ask for the price at your dose in writing before you prepay.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC), or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2). The most common side effects include nausea, diarrhea, vomiting, constipation and stomach pain.
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. The FDA warned on Nov. 9, 2026, that GLP-1 medicines may raise the risk of NAION, a rare eye condition that can cause sudden vision loss in one eye; call your provider right away if that happens (FDA). Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
Who wrote and medically reviewed this page?
Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.
Labels and trials read November 1 to 5, 2026. Other programs’ prices checked November 1, 2026.
- How we checked. The doses, schedule and warnings come from the Zepbound prescribing information (revised August 2026). The 2018 trial’s results come from the American College of Cardiology’s summary of its paper in The Lancet; SURMOUNT-1’s from its paper in The New England Journal of Medicine, as reported by Healio; SURMOUNT-MAINTAIN’s from its paper in The Lancet. Lilly’s statement is as quoted by ConsumerAffairs (January 16, 2026), and the 2026 review as summarized by News-Medical (September 1, 2026). NexLife’s prices come from our pricing page (November 5, 2026); other programs’ prices are as our reviews list them, checked November 1, 2026. We don’t give a microdose: your provider decides.
- Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email hello@nexlife.us and we’ll fix it.
- How we work. How we review programs · GLP-1 price index · Is NexLife legit? · States NexLife serves
Paying less elsewhere? We match it.†
Microdose or full dose? Your price stays the same.
Start online in about 3 minutes, and a licensed provider decides your dose. $115 a month on the 12-month plan, or $129 month to month, at every dose.
4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026) · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
- 1Tell us about you
Start online with your health history.
- 2A licensed provider decides
Online, following your state’s rules. You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.
Sources
- Zepbound (tirzepatide) prescribing information, Eli Lilly (revised August 2026). Read November 15, 2026.
- Frias JP et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. The Lancet 2018; 392: 2180–93. Read November 5, 2026.
- American College of Cardiology. Efficacy and Safety of LY3298176 (trial summary, with results by dose). Read November 5, 2026.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). The New England Journal of Medicine 2022; 387: 205–16. Read November 5, 2026.
- Healio. Weekly tirzepatide confers substantial weight loss in obesity without diabetes: SURMOUNT-1 (June 4, 2022). Read November 5, 2026.
- Horn DB et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). The Lancet 2026; 407: 2305–18. Read October 22, 2026.
- ConsumerAffairs. GLP-1 microdoses not a good idea, doctors warn (January 16, 2026), with Lilly’s statement on microdosing. Read November 5, 2026.
- News-Medical. GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them? (September 1, 2026), on Panlilio MA et al., Multisystem benefits of GLP-1 microdosing: a narrative review, Cureus 2026; 18(7): e113635. Read November 5, 2026.
- STAT. Microdosing aims to extend the lifespan of the GLP-1 compounding market (November 4, 2025). Read November 5, 2026.
- Noom: how much does Noom cost? (microdose tirzepatide plan). Checked November 15, 2026.
- Raeliva: compounded microdose tirzepatide. Checked November 15, 2026.
- Remedy Meds: homepage, plans and microdose option. Checked November 15, 2026.
- LillyDirect: Zepbound self-pay prices. Checked November 15, 2026.
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (April 1, 2026). Read November 15, 2026.
- Pharmacy Times. FDA moves to permanently close the door on compounded GLP-1s (May 1, 2026). Read November 5, 2026.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Read November 15, 2026.
- U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (July 26, 2024). Read November 15, 2026.
- U.S. Pharmacopeia. USP General Chapter 797: Pharmaceutical Compounding, Sterile Preparations. Read November 2, 2026.
- Centers for Medicare & Medicaid Services. Medicare.gov: weight loss drugs (GLP-1 Bridge). Read November 15, 2026.
- NexLife: pricing, every plan. Checked November 15, 2026.
- NexLife: microdose tirzepatide program. Checked November 5, 2026.